Effective Management of
Nausea and Vomiting (CINV): Appropriate
Treatment for Improved Outcomes
A continuing medical education activity sponsored by NAMCP and AAMCN.
This activity is an archive from the
live session from the 2018 Spring Managed Care Forum. If you
participated in the live session, you are not eligible for
continuing education credits from this archive.
This activity is valid from August 1, 2018 to August 1, 2019
Instructions for CME/CNE: Complete the pre-test, listen to the audio
and view the slides, complete the post test, complete the evaluation
form and hit submit. You will be asked to enter your name and email
address on the pre-test, evaluation and post-test. If you close your
internet browser without completing the post test, you will have ONE
more opportunity to complete. A score of 70% must be achieved on the
post test to receive continuing education credits. If you do not
pass the post test after two attempts, you will not be eligible to
try again. Once you complete the evaluation form and score 70% or
higher on your post test, you will automatically be given your
To print or save your certificate, you will need to click on the
“download” button and either print or save.
Audience: This activity is intended for
healthcare professionals practicing in managed care environments.
This presentation is supported by
an educational grant from Helsinn
Chemotherapy-induced nausea and vomiting (CINV) is a condition in
which patients become physically ill following the administration of
chemotherapy drugs and is one of the most feared side effects of
chemotherapy treatments. Patients who suffer from acute CINV
typically experience symptoms within the first 24 hours following
treatment while delayed CINV usually occurs within 24 to 72 hours
after chemotherapy and can potentially last for several days. Risk
factors for this condition fall into patient-specific and
therapy-specific categories thus the treatment of CINV can vary
depending on the patient’s response to the therapy introduced after
chemotherapy. Utilizing an appropriate degree of prophylaxis for the
first cycle of chemotherapy is critical to prevent breakthrough CINV,
which is difficult to manage and can lead to later anticipatory
vomiting during subsequent cycles of therapy. The goal of selecting
optimal antiemetic therapy continues to be based on the patient’s
individualized treatment plans with the emergence of newer agents
and patient-related risk factors, as well as the rapid evolution of
guidelines for the management of CINV. Optimizing antiemetic usage
requires awareness of available and emerging agents, as well as of
the unique characteristics of these therapies that affect their role
in CINV management. Because antiemetic medication has such a high
success rate, chemotherapy patients no longer have to accept nausea,
vomiting, and a decreased quality of life as an automatic
consequence of treating cancer.
Upon completion of this
activity, participants will be able to:
Analyze the impact, occurrence and
risk of CINV with commonly used chemotherapy regimens
Examine the emerging clinical trial
data for the safety and efficacy of newly approved agents
Review the current and emerging
chemotherapeutic agents for the treatment of CINV
Differentiate antiemetic regimens
for acute, delayed, breakthrough, and refractory CINV
Identify educational tactics to
promote effective communication and coordination of care,
address potential adverse events, and help patients improve CINV
||Susan Urba, MD
Professor of Internal Medicine
Division of Hematology/Oncology
Symptom Management & Supportive Care Program
University of Michigan Comprehensive Cancer Center
has no relevant financial relationships to disclose.
MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships
Jacqueline Cole, RN, MS, CMCN has no relevant financial
relationships to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is
accredited by the Accreditation Council for Continuing Medical
Education to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category I creditsTM.
The American Association of Managed Care Nurses is accredited as a
provider of continuing nursing
education by the American Nurses Credentialing Center’s Commission
Nurses who complete this activity and achieve a passing score will
receive 1 hour in continuing
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This presentation is supported by an
educational grant from Helsinn
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue